Expand OCUL Menu
OCUL MENU

OCUL Latest Press Releases

-- December 13, 2024 --

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- December 10, 2024 --

Ocular Therapeutix to Present at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:30 AM

-- December 2, 2024 --

Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1 Globe Newswire 7:30 AM

-- November 26, 2024 --

Ocular Therapeutix to Participate in December Investor and Scientific Conferences Globe Newswire 7:30 AM

-- November 14, 2024 --

Ocular Therapeutix Reports Third Quarter 2024 Results and Business Highlights Globe Newswire 7:00 AM

-- November 13, 2024 --

Ocular Therapeutix to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV Globe Newswire 7:30 AM

-- November 12, 2024 --

Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business Officer Globe Newswire 7:30 AM

-- November 6, 2024 --

Ocular Therapeutix to Report Third Quarter 2024 Results on November 14, 2024 Globe Newswire 7:30 AM

-- October 15, 2024 --

Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD Globe Newswire 7:30 AM

-- October 9, 2024 --

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Ocular Therapeutix to Present at October Ophthalmology Meetings Globe Newswire 7:30 AM

-- September 25, 2024 --

Ocular Therapeutix to Present at the UBS Virtual Opthalmology Day 2024 Globe Newswire 7:30 AM

-- September 12, 2024 --

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 5, 2024 --

Ocular Therapeutix to Present at September Retina Meetings Globe Newswire 7:30 AM

-- September 4, 2024 --

Ocular Therapeutix to Present at Two Investor Conferences in September Globe Newswire 7:30 AM

-- August 9, 2024 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- August 7, 2024 --

Ocular Therapeutix Reports Second Quarter 2024 Results Globe Newswire 7:10 AM
Ocular Therapeutix Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD Globe Newswire 7:00 AM

-- July 31, 2024 --

Ocular Therapeutix to Report Second Quarter 2024 Financial Results on August 7, 2024 Globe Newswire 7:30 AM

-- July 30, 2024 --

Ocular Therapeutix Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study Globe Newswire 7:30 AM

-- July 18, 2024 --

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM